Foundations Investment Advisors LLC Purchases 784 Shares of Merck & Co., Inc. (NYSE:MRK)

Foundations Investment Advisors LLC increased its position in shares of Merck & Co., Inc. (NYSE:MRKGet Rating) by 17.7% in the 2nd quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 5,208 shares of the company’s stock after purchasing an additional 784 shares during the quarter. Foundations Investment Advisors LLC’s holdings in Merck & Co., Inc. were worth $485,000 at the end of the most recent reporting period.

Several other institutional investors and hedge funds have also bought and sold shares of MRK. Legacy Private Trust Co. raised its stake in Merck & Co., Inc. by 12.8% during the second quarter. Legacy Private Trust Co. now owns 39,357 shares of the company’s stock worth $3,588,000 after acquiring an additional 4,481 shares in the last quarter. Astoria Portfolio Advisors LLC. raised its stake in Merck & Co., Inc. by 14.5% during the second quarter. Astoria Portfolio Advisors LLC. now owns 7,254 shares of the company’s stock worth $661,000 after acquiring an additional 918 shares in the last quarter. Chesley Taft & Associates LLC raised its stake in Merck & Co., Inc. by 0.3% during the second quarter. Chesley Taft & Associates LLC now owns 55,743 shares of the company’s stock worth $5,082,000 after acquiring an additional 143 shares in the last quarter. Massmutual Trust Co. FSB ADV raised its stake in Merck & Co., Inc. by 2.0% during the second quarter. Massmutual Trust Co. FSB ADV now owns 144,613 shares of the company’s stock worth $13,184,000 after acquiring an additional 2,821 shares in the last quarter. Finally, Crestwood Advisors Group LLC raised its stake in Merck & Co., Inc. by 0.6% during the second quarter. Crestwood Advisors Group LLC now owns 205,904 shares of the company’s stock worth $18,772,000 after acquiring an additional 1,166 shares in the last quarter. Institutional investors own 73.33% of the company’s stock.

Merck & Co., Inc. Price Performance

Merck & Co., Inc. stock opened at $87.72 on Friday. The stock has a market capitalization of $222.22 billion, a price-to-earnings ratio of 13.43, a PEG ratio of 1.18 and a beta of 0.33. Merck & Co., Inc. has a 52-week low of $70.89 and a 52-week high of $95.72. The stock’s 50 day moving average price is $89.45 and its two-hundred day moving average price is $87.56. The company has a debt-to-equity ratio of 0.66, a quick ratio of 1.15 and a current ratio of 1.39.

Merck & Co., Inc. (NYSE:MRKGet Rating) last issued its earnings results on Thursday, July 28th. The company reported $1.87 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $1.67 by $0.20. Merck & Co., Inc. had a return on equity of 48.45% and a net margin of 29.00%. The company had revenue of $14.59 billion for the quarter, compared to analysts’ expectations of $13.85 billion. During the same period last year, the business earned $1.31 EPS. Merck & Co., Inc.’s quarterly revenue was up 28.0% compared to the same quarter last year. On average, equities analysts predict that Merck & Co., Inc. will post 7.33 earnings per share for the current year.

Merck & Co., Inc. Announces Dividend

The business also recently disclosed a quarterly dividend, which will be paid on Friday, October 7th. Shareholders of record on Thursday, September 15th will be paid a dividend of $0.69 per share. This represents a $2.76 annualized dividend and a yield of 3.15%. The ex-dividend date of this dividend is Wednesday, September 14th. Merck & Co., Inc.’s dividend payout ratio (DPR) is presently 42.27%.

Analyst Ratings Changes

MRK has been the subject of several recent research reports. Mizuho initiated coverage on Merck & Co., Inc. in a research note on Friday, June 24th. They issued a “buy” rating and a $100.00 price objective for the company. SVB Leerink upped their price objective on Merck & Co., Inc. from $105.00 to $109.00 and gave the company an “outperform” rating in a research note on Monday, September 12th. Atlantic Securities upped their price objective on Merck & Co., Inc. from $105.00 to $110.00 and gave the company an “overweight” rating in a research note on Wednesday, July 13th. Daiwa Capital Markets raised Merck & Co., Inc. from a “neutral” rating to a “buy” rating and upped their price objective for the company from $89.00 to $102.00 in a research note on Wednesday, July 6th. Finally, Cowen upped their price objective on Merck & Co., Inc. from $95.00 to $102.00 and gave the company a “market perform” rating in a research note on Monday, June 27th. Seven equities research analysts have rated the stock with a hold rating, eleven have assigned a buy rating and two have assigned a strong buy rating to the company. According to MarketBeat, Merck & Co., Inc. has an average rating of “Moderate Buy” and a consensus target price of $98.28.

Merck & Co., Inc. Company Profile

(Get Rating)

Merck & Co, Inc operates as a healthcare company worldwide. It operates through two segments, Pharmaceutical and Animal Health. The Pharmaceutical segment offers human health pharmaceutical products in the areas of oncology, hospital acute care, immunology, neuroscience, virology, cardiovascular, and diabetes, as well as vaccine products, such as preventive pediatric, adolescent, and adult vaccines.

Further Reading

Want to see what other hedge funds are holding MRK? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Merck & Co., Inc. (NYSE:MRKGet Rating).

Institutional Ownership by Quarter for Merck & Co., Inc. (NYSE:MRK)

Receive News & Ratings for Merck & Co. Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Merck & Co. Inc. and related companies with MarketBeat.com's FREE daily email newsletter.